TNFRSF8 and bone metastasis: Notably, the FDA‐approved FAST‐01 trial showed that FLASH‐RT effectively relieved bone metastasis pain in 10 patients with equal or lower toxicity than conventional RT.[96] Another case reported minimal skin toxicity in a CD30+ T‐cell lymphoma patient treated with 15 Gy FLASH‐RT in 90 ms, despite prior severe reactions to conventional RT.[97] These cases suggest that the tissue‐sparing effect observed in mice may extend to humans.